Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey

Kidney involvement in systemic light-chain amyloidosis (AL-SA) is associated with rapidly declining kidney function and increased mortality. The optimal kidney replacement therapy for AL-SA patients has not been ascertained. There is some suggestion that peritoneal dialysis (PD) may be safer than in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Onco-Nephrology 2024-10, Vol.8 (3), p.79-82
Hauptverfasser: Pantanowitz, Joshua, Bender, Filitsa, Bursic, Alexandra, Piraino, Beth, Amarapurkar, Pooja
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 82
container_issue 3
container_start_page 79
container_title Journal of Onco-Nephrology
container_volume 8
creator Pantanowitz, Joshua
Bender, Filitsa
Bursic, Alexandra
Piraino, Beth
Amarapurkar, Pooja
description Kidney involvement in systemic light-chain amyloidosis (AL-SA) is associated with rapidly declining kidney function and increased mortality. The optimal kidney replacement therapy for AL-SA patients has not been ascertained. There is some suggestion that peritoneal dialysis (PD) may be safer than intermittent hemodialysis (iHD) for these patients. However, the clinical course of these patients can be rather complex and daunting, both for the patient and for the treating physicians. There is also a lack of data describing the associated challenges and outcomes, especially with respect to the use of chemotherapy, hematopoietic stem cell transplantation (HSCT), and kidney transplantation (KT) in patients with AL-SA who are on PD for end stage kidney disease (ESKD). We present the interesting case of a 41-year-old patient on PD for ESKD due to AL-SA, for which she underwent chemotherapy and HSCT. She ultimately was able to receive a successful KT. Through this case, we aim to highlight the complexities involved in the treatment journey of patients with AL-SA and kidney disease. We present evidence for greater hemodynamic stability with PD as compared to iHD and thus gentler ultrafiltration, information on anticancer agent dosing for PD, and finally offer hope for the feasibility of PD and KT to support a better quality of life for AL-SA patients with kidney disease.
doi_str_mv 10.1177/23993693241273573
format Article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_23993693241273573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_23993693241273573</sage_id><sourcerecordid>10.1177_23993693241273573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c813-fa11ba4888b8211c1128b839dd945f6d5c4a77b804fa99e06f40bd9bd158834e3</originalsourceid><addsrcrecordid>eNp9UMtKAzEUDaJg0X6Au3yAU3MnM03iToovKLiw--FOHm3KTFKS6WLw5x2trgRX93Ael8Mh5AbYAkCIu5IrxZeKlxWUgteCn5HZF1dwwcT5L54Ml2Se854xxssSONQz8vE-5sH2XtPOb3dDoXfoA8V-7KI3Mft8Sw82-SEGix01Hrvxm8Rg6JAw5EOHYcDBx3BP1zbnGDJ1KfYUqbH9ZPNhS0c70HzUetLdsaP7eEzBjtfkwmGX7fznXpHN0-Nm9VKs355fVw_rQkvghUOAFispZStLAA1QTogrY1RVu6WpdYVCtJJVDpWybOkq1hrVGqil5JXlVwROb3WKOSfrmkPyPaaxAdZ87df82W_KLE6ZjFvbfPedGv4T-ASgb3Ka</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey</title><source>SAGE Complete A-Z List</source><creator>Pantanowitz, Joshua ; Bender, Filitsa ; Bursic, Alexandra ; Piraino, Beth ; Amarapurkar, Pooja</creator><creatorcontrib>Pantanowitz, Joshua ; Bender, Filitsa ; Bursic, Alexandra ; Piraino, Beth ; Amarapurkar, Pooja</creatorcontrib><description>Kidney involvement in systemic light-chain amyloidosis (AL-SA) is associated with rapidly declining kidney function and increased mortality. The optimal kidney replacement therapy for AL-SA patients has not been ascertained. There is some suggestion that peritoneal dialysis (PD) may be safer than intermittent hemodialysis (iHD) for these patients. However, the clinical course of these patients can be rather complex and daunting, both for the patient and for the treating physicians. There is also a lack of data describing the associated challenges and outcomes, especially with respect to the use of chemotherapy, hematopoietic stem cell transplantation (HSCT), and kidney transplantation (KT) in patients with AL-SA who are on PD for end stage kidney disease (ESKD). We present the interesting case of a 41-year-old patient on PD for ESKD due to AL-SA, for which she underwent chemotherapy and HSCT. She ultimately was able to receive a successful KT. Through this case, we aim to highlight the complexities involved in the treatment journey of patients with AL-SA and kidney disease. We present evidence for greater hemodynamic stability with PD as compared to iHD and thus gentler ultrafiltration, information on anticancer agent dosing for PD, and finally offer hope for the feasibility of PD and KT to support a better quality of life for AL-SA patients with kidney disease.</description><identifier>ISSN: 2399-3693</identifier><identifier>EISSN: 2399-3707</identifier><identifier>DOI: 10.1177/23993693241273573</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>Journal of Onco-Nephrology, 2024-10, Vol.8 (3), p.79-82</ispartof><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c813-fa11ba4888b8211c1128b839dd945f6d5c4a77b804fa99e06f40bd9bd158834e3</cites><orcidid>0009-0005-2533-4589 ; 0000-0001-8783-913X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/23993693241273573$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/23993693241273573$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids></links><search><creatorcontrib>Pantanowitz, Joshua</creatorcontrib><creatorcontrib>Bender, Filitsa</creatorcontrib><creatorcontrib>Bursic, Alexandra</creatorcontrib><creatorcontrib>Piraino, Beth</creatorcontrib><creatorcontrib>Amarapurkar, Pooja</creatorcontrib><title>Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey</title><title>Journal of Onco-Nephrology</title><description>Kidney involvement in systemic light-chain amyloidosis (AL-SA) is associated with rapidly declining kidney function and increased mortality. The optimal kidney replacement therapy for AL-SA patients has not been ascertained. There is some suggestion that peritoneal dialysis (PD) may be safer than intermittent hemodialysis (iHD) for these patients. However, the clinical course of these patients can be rather complex and daunting, both for the patient and for the treating physicians. There is also a lack of data describing the associated challenges and outcomes, especially with respect to the use of chemotherapy, hematopoietic stem cell transplantation (HSCT), and kidney transplantation (KT) in patients with AL-SA who are on PD for end stage kidney disease (ESKD). We present the interesting case of a 41-year-old patient on PD for ESKD due to AL-SA, for which she underwent chemotherapy and HSCT. She ultimately was able to receive a successful KT. Through this case, we aim to highlight the complexities involved in the treatment journey of patients with AL-SA and kidney disease. We present evidence for greater hemodynamic stability with PD as compared to iHD and thus gentler ultrafiltration, information on anticancer agent dosing for PD, and finally offer hope for the feasibility of PD and KT to support a better quality of life for AL-SA patients with kidney disease.</description><issn>2399-3693</issn><issn>2399-3707</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UMtKAzEUDaJg0X6Au3yAU3MnM03iToovKLiw--FOHm3KTFKS6WLw5x2trgRX93Ael8Mh5AbYAkCIu5IrxZeKlxWUgteCn5HZF1dwwcT5L54Ml2Se854xxssSONQz8vE-5sH2XtPOb3dDoXfoA8V-7KI3Mft8Sw82-SEGix01Hrvxm8Rg6JAw5EOHYcDBx3BP1zbnGDJ1KfYUqbH9ZPNhS0c70HzUetLdsaP7eEzBjtfkwmGX7fznXpHN0-Nm9VKs355fVw_rQkvghUOAFispZStLAA1QTogrY1RVu6WpdYVCtJJVDpWybOkq1hrVGqil5JXlVwROb3WKOSfrmkPyPaaxAdZ87df82W_KLE6ZjFvbfPedGv4T-ASgb3Ka</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Pantanowitz, Joshua</creator><creator>Bender, Filitsa</creator><creator>Bursic, Alexandra</creator><creator>Piraino, Beth</creator><creator>Amarapurkar, Pooja</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0009-0005-2533-4589</orcidid><orcidid>https://orcid.org/0000-0001-8783-913X</orcidid></search><sort><creationdate>202410</creationdate><title>Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey</title><author>Pantanowitz, Joshua ; Bender, Filitsa ; Bursic, Alexandra ; Piraino, Beth ; Amarapurkar, Pooja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c813-fa11ba4888b8211c1128b839dd945f6d5c4a77b804fa99e06f40bd9bd158834e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pantanowitz, Joshua</creatorcontrib><creatorcontrib>Bender, Filitsa</creatorcontrib><creatorcontrib>Bursic, Alexandra</creatorcontrib><creatorcontrib>Piraino, Beth</creatorcontrib><creatorcontrib>Amarapurkar, Pooja</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of Onco-Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pantanowitz, Joshua</au><au>Bender, Filitsa</au><au>Bursic, Alexandra</au><au>Piraino, Beth</au><au>Amarapurkar, Pooja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey</atitle><jtitle>Journal of Onco-Nephrology</jtitle><date>2024-10</date><risdate>2024</risdate><volume>8</volume><issue>3</issue><spage>79</spage><epage>82</epage><pages>79-82</pages><issn>2399-3693</issn><eissn>2399-3707</eissn><abstract>Kidney involvement in systemic light-chain amyloidosis (AL-SA) is associated with rapidly declining kidney function and increased mortality. The optimal kidney replacement therapy for AL-SA patients has not been ascertained. There is some suggestion that peritoneal dialysis (PD) may be safer than intermittent hemodialysis (iHD) for these patients. However, the clinical course of these patients can be rather complex and daunting, both for the patient and for the treating physicians. There is also a lack of data describing the associated challenges and outcomes, especially with respect to the use of chemotherapy, hematopoietic stem cell transplantation (HSCT), and kidney transplantation (KT) in patients with AL-SA who are on PD for end stage kidney disease (ESKD). We present the interesting case of a 41-year-old patient on PD for ESKD due to AL-SA, for which she underwent chemotherapy and HSCT. She ultimately was able to receive a successful KT. Through this case, we aim to highlight the complexities involved in the treatment journey of patients with AL-SA and kidney disease. We present evidence for greater hemodynamic stability with PD as compared to iHD and thus gentler ultrafiltration, information on anticancer agent dosing for PD, and finally offer hope for the feasibility of PD and KT to support a better quality of life for AL-SA patients with kidney disease.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/23993693241273573</doi><tpages>4</tpages><orcidid>https://orcid.org/0009-0005-2533-4589</orcidid><orcidid>https://orcid.org/0000-0001-8783-913X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2399-3693
ispartof Journal of Onco-Nephrology, 2024-10, Vol.8 (3), p.79-82
issn 2399-3693
2399-3707
language eng
recordid cdi_crossref_primary_10_1177_23993693241273573
source SAGE Complete A-Z List
title Systemic light-chain amyloidosis, peritoneal dialysis, and transplantation: Lessons from a demanding yet successful journey
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T23%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20light-chain%20amyloidosis,%20peritoneal%20dialysis,%20and%20transplantation:%20Lessons%20from%20a%20demanding%20yet%20successful%20journey&rft.jtitle=Journal%20of%20Onco-Nephrology&rft.au=Pantanowitz,%20Joshua&rft.date=2024-10&rft.volume=8&rft.issue=3&rft.spage=79&rft.epage=82&rft.pages=79-82&rft.issn=2399-3693&rft.eissn=2399-3707&rft_id=info:doi/10.1177/23993693241273573&rft_dat=%3Csage_cross%3E10.1177_23993693241273573%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.1177_23993693241273573&rfr_iscdi=true